Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Six-month avelumab maintenance in advanced or metastatic urothelial cancer
NL-OMON54124Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of avelumab in transitional cell carcinoma (TCC) and bladder cancer, sponsored by Amsterdam University Medical Center. Primary endpoint: 18 months overall survival. Started Nov 2021; status: recruiting.
02
Drugs
avelumab
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON54124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54124.